213 related articles for article (PubMed ID: 31328222)
1. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis.
Novello M; Stocchi L; Holubar S; Shawki S; Lipman J; Gorgun E; Hull T; Steele SR
Int J Colorectal Dis; 2019 Mar; 34(3):451-457. PubMed ID: 30535559
[TBL] [Abstract][Full Text] [Related]
3. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Efken P; Mohl W; Hoffstadt M; Krause T; Schweitzer A; Schnoy E; Atreya R; Teich N; Trentmann L; Ehehalt R; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2024 May; 30(5):746-756. PubMed ID: 37523666
[TBL] [Abstract][Full Text] [Related]
6. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
8. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.
Lau C; Dubinsky M; Melmed G; Vasiliauskas E; Berel D; McGovern D; Ippoliti A; Shih D; Targan S; Fleshner P
Ann Surg; 2015 Mar; 261(3):487-96. PubMed ID: 24950263
[TBL] [Abstract][Full Text] [Related]
9. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
Lightner AL; McKenna NP; Tse CS; Raffals LE; Loftus EV; Mathis KL
Aliment Pharmacol Ther; 2018 Mar; 47(5):573-580. PubMed ID: 29250800
[TBL] [Abstract][Full Text] [Related]
10. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease.
Waterman M; Xu W; Dinani A; Steinhart AH; Croitoru K; Nguyen GC; McLeod RS; Greenberg GR; Cohen Z; Silverberg MS
Gut; 2013 Mar; 62(3):387-94. PubMed ID: 22619367
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease.
Yung DE; Horesh N; Lightner AL; Ben-Horin S; Eliakim R; Koulaouzidis A; Kopylov U
Inflamm Bowel Dis; 2018 Oct; 24(11):2327-2338. PubMed ID: 29788385
[TBL] [Abstract][Full Text] [Related]
12. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
Yamada A; Komaki Y; Patel N; Komaki F; Aelvoet AS; Tran AL; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Am J Gastroenterol; 2017 Sep; 112(9):1423-1429. PubMed ID: 28719595
[TBL] [Abstract][Full Text] [Related]
13. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
Park KT; Sceats L; Dehghan M; Trickey AW; Wren A; Wong JJ; Bensen R; Limketkai BN; Keyashian K; Kin C
Aliment Pharmacol Ther; 2018 Aug; 48(3):340-346. PubMed ID: 29876995
[TBL] [Abstract][Full Text] [Related]
14. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.
Shwaartz C; Fields AC; Sobrero M; Cohen BD; Divino CM
J Gastrointest Surg; 2016 Sep; 20(9):1636-42. PubMed ID: 27405310
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection.
Mitsuya JB; Gonzalez R; Thomas R; El-Baba M
J Pediatr Gastroenterol Nutr; 2019 Mar; 68(3):334-338. PubMed ID: 30247424
[TBL] [Abstract][Full Text] [Related]
17. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
19. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
Helwig U; Kostev K; Schmidt C
J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
[TBL] [Abstract][Full Text] [Related]
20. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
